Development of systemic lupus erythematosus in a patient with rheumatoid arthritis following treatment conversion of infliximab to adalimumab.
Systemic lupus erythematosus (SLE)-like syndromes and the development of lupus-related autoantibodies are known to occur during treatment with certain medications. Here a case of complete SLE conversion in a patient with rheumatoid arthritis following sequential treatment with infliximab and adalimumab is reported. Potential mechanisms for development of SLE with this treatment regimen are discussed, as well as the need for further exploration into autoimmune phenomenon with the use of immunobiologic agents.